A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo.
Australia, China, Hong Kong, Japan, South Korea, Turkey, UK, USA
https://clinicaltrials.gov/study/NCT06722235?term=tak-079-3002&rank=2
Actively Recruiting